Survey of Ophthalmology
Volume 48, Issue 2, Supplement , Pages S47-S51 , April 2003

Role of Alpha-2 Agonists in Neuroprotection

References 

  1. Ballif BA, Blenis J. Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ. 2001;12:397–408
  2. Burke J, Manlapaz C, Kharlamb A, et al.  Therapeutic use of α2-adrenceptor agonists in glaucoma. In:  Lanier SM,  Limbird LE editor. Alpha-Adrenergic Receptors Structure, Function and Therapeutic Implications. Reading, UK: Harwood Academic Publishers; 1996;p. 179–187
  3. Bylund DB, Chacko DM. Characterization of alpha2 adrenergic receptor subtypes in human ocular tissue. Invest Ophthalmol Vis Sci. 1999;40:2299–2306
  4. Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma. 2002;11:119–126
  5. Kent A, Nussdorf J, Fellows D, et al.  Brimonidine concentrations in the posterior segment of patients during Alphagan treatment. Ophthalmology. 2001;108:784–787
  6. Kerrigan LA, Zack DJ, Quigley HA, Smith SD, Pease ME. TUNEL-positive ganglion cells in human primary open-angle glaucoma. Arch Ophthalmol. 1997;115:1031–1035
  7. Lafuente MP, Villegas-Perez MP, Mayor S, et al.  Neuroprotective effects of brimonidine against transient ischemia-induced retinal ganglion cell death (a dose response in vivo study). Exp Eye Res. 2002;74:181–189
  8. Lafuente MP, Villegas-Perez MP, Sobrado-Calvo P, et al.  Neuroprotective effects of alpha-2 adrenergic agonists against ischemia-mediated retinal ganglion cell death. Invest Ophthalmol Vis Sci. 2001;42:2074–2084
  9. Lai R, Chun T, Hasson D, et al.  Alpha-2 adrenoceptor agonist protects retinal function after acute retinal ischemic injury in the rat. Vis Neurosci. 2002;19:175–185
  10. Mansour-Robaey S, Clark DB, Wang YC, et al.  Effects of ocular injury and administration of brain-derived neurotrophic factor on survival and regrowth of axotomized retinal ganglion cells. Proc Natl Acad Sci USA. 1994;91:1632–1636
  11. Meyer-Franke A, Kaplan MR, Pfrieger FW, Barres BA. Characterization of the signaling interactions that promote the survival and growth of developing retinal ganglion cells in culture. Neuron. 1995;15:805–819
  12. Munk S, Harcourt D, Arasasingham P, et al.  Analogs of UK-14,304 (structural features responsible for α2-adrenoceptor activity). Bioorg Med Chem Lett. 1995;5:1745–1750
  13. Tatton WG. Apoptotic mechanisms in neurodegeneration (possible relevance to glaucoma). Eur J Ophthalmol. 1999;9(Suppl 1):S22–S29
  14. Tatton NA, Tezel G, Insolia SA, et al.  In situ detection of apoptosis in normal pressure glaucoma. A preliminary examination. Surv Ophthalmol. 2001;45:S268–S272
  15. Tatton WG, Chalmers-Redman RME, Sud A, et al.  Maintaining mitochondrial membrane impermeability (an opportunity for new therapy in glaucoma?). Surv Ophthalmol. 2001;45(Suppl 3):S277–S283
  16. Weinreb RN, Levin LA. Is neuroprotection a viable therapy for glaucoma?. Arch Ophthalmol. 1999;117:1540–1544
  17. Wheeler LA, Gil DW, WoldeMussie E. Role of alpha2 adrenergic receptors in neuroprotection and glaucoma. Surv Ophthalmol. 2001;45(Suppl 3):S290–S294
  18. Wheeler LA, Tatton NA, Elstner M, et al.  Alpha-2 adrenergic receptor activation by brimonidine reduces neuronal apoptosis through Akt (Protein Kinase B) dependent new synthesis of BCL-2. Invest Ophthalmol Vis Sci. 2001;42:S411
  19. WoldeMussie E, Ruiz G, Wijono M, Wheeler LA. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci. 2001;42:2849–2855
  20. Xia Z, Dickens M, Raingeaud J, et al.  Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science. 1995;270:1326–1331
  21. Yoles E, Wheeler L, Schwartz M. Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration. Invest Ophthalmol Vis Sci. 1999;40:65–73
  22. Zha J, Harada H, Osipov K, et al.  BH3 Domain of BAD is required for heterodimerization with BCL-XL and pro-apoptotic activity. J Biol Chem. 1997;272:24101–24104

PII: S0039-6257(03)00004-3

doi: 10.1016/S0039-6257(03)00004-3

Survey of Ophthalmology
Volume 48, Issue 2, Supplement , Pages S47-S51 , April 2003

Article Tools

* Image Usage & Resolution